A Novel Formulation of the Anticancer Drug Candidate CX5461 that Relies on Metal Chemistry and Liposomal Nanotechnology: Development for use in Treatment of Pancreatic Cancer's with BRCA Deficiencies; an Orphan Indication

依赖金属化学和脂质体纳米技术的抗癌候选药物 CX5461 的新配方：开发用于治疗 BRCA 缺陷的胰腺癌；

• 批准号: 446517
• 负责人: Bally Marcel B
• 金额: $ 55.73万
• 依托单位: BC Cancer, part of PHSA (Vancouver)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-04-01 至 2026-04-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=446517&lang=en
• 关键词: Brca Deficiencies; Cx5461; Drug Development; Liposomes; Metal Chemistry; Mice; Pancreatic Cancer Efficacy Models; Preclinical; Safety Pharmacology; Skin Toxicity

CX-5461 is an interesting anti-cancer drug candidate. It was originally developed as an agent that inhibits a protein that is important in producing RNA, the material in cells responsible for producing proteins. Since that time it has been shown to act as

CX-5461是一种有趣的抗癌候选药物。它最初是作为一种抑制蛋白质的药物开发的，这种蛋白质在产生RNA中很重要，RNA是细胞中负责产生蛋白质的物质。从那时起，它就被证明是